Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma

Transplantation and Cellular Therapy(2021)

Cited 3|Views4
No score
Abstract
•We reviewed outcomes in 20 patients with secondary central nervous system (CNS) lymphoma undergoing allogeneic blood or marrow transplantation.•All patients received nonmyeloablative conditioning and post-transplantation cyclophosphamide.•Prolonged disease-free survival was achieved in ∼50% of patients.•Myeloablative conditioning and CNS radiotherapy were not required for remission.
More
Translated text
Key words
CNS lymphoma,Post-transplantation cyclophosphamide,Haploidentical stem cell transplantation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined